As Jenn Powell's MS progression continues, she's had to make the difficult decision to step away from the stress of full-time ...

For decades, multiple sclerosis research has focused on myelin, the insulation around the brain's wiring. Scientists paid ...

Oral tobacco use, also known as moist snuff, is associated with slower progression of multiple sclerosis (MS), a new study shows. "Our finding that snuff use is not associated with worse disease ...

A genome-wide association study (GWAS) including more than 22,000 people with multiple sclerosis (MS) has uncovered the first genetic variant associated with faster progression of the autoimmune ...

In the coming weeks, Quantum Biopharma will seek FDA permission for a clinical trial testing Lucid-MS, its therapy to slow myelin loss in MS.

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Please provide your email address to receive an email when new articles are posted on . Researchers added a treatment arm to an ongoing study of nine patients with MS who were given clemastine ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...